Publicacions en col·laboració amb investigadors/es de Hospital del Mar (19)

2017

  1. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028

  2. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

    Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321

  3. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

    Actas dermo-sifiliograficas, Vol. 108, Núm. 1, pp. 52-58

  4. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 52-58

  5. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort

    British Journal of Dermatology

2016

  1. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

    Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209

  2. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

    Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950

  3. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

    Actas Dermo-Sifiliograficas, Vol. 106, Núm. 8, pp. 638-643

  2. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

    Actas dermo-sifiliograficas, Vol. 106, Núm. 8, pp. 638-643

  3. Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: Baseline characteristics of patients in the aquiles study

    Actas Dermo-Sifiliograficas, Vol. 106, Núm. 1, pp. 35-43

  4. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 1, pp. 156-163

  5. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 5, pp. 858-864

  6. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice

    Journal of Dermatological Treatment, Vol. 26, Núm. 6, pp. 502-506

2014

  1. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobadaderm Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 28, Núm. 7, pp. 907-914

2013

  1. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study

    Actas Dermo-Sifiliograficas, Vol. 104, Núm. 9, pp. 807-814

  2. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 27, Núm. 11, pp. 1366-1374

  3. Mental health self-assessment in patients with moderate to severe psoriasis: An observational, multicenter study of 1164 patients in Spain (The VACAP study)

    Actas Dermo-Sifiliograficas, Vol. 104, Núm. 10, pp. 897-903

2012

  1. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials

    Archives of Dermatology, Vol. 148, Núm. 4, pp. 463-470